Exelixis (EXEL) Interest Coverage Ratio (2010 - 2018)
Exelixis (EXEL) posted quarterly Interest Coverage Ratio of 128.37 for Q2 2026, down 34.19% year-over-year from 195.05 in Q2 2025, and down 97.93% quarter-over-quarter from 6189.89 in Q1 2026.
Powered by 
Analysis
Exelixis (EXEL) Interest Coverage Ratio (2010 - 2018) Analysis & Trends
Exelixis' Interest Coverage Ratio history runs 17 years deep, the most recent figure standing at 128.37 for Q2 2026.
- In Q2 2026, Interest Coverage Ratio fell 34.19% year-over-year to 128.37; the TTM figure through Apr 2026 stood at 478.38 (down 39.86% YoY), while the FY2026 annual figure was 9.95, up 41.49% from the prior year.
- Interest Coverage Ratio for Q2 2026 stood at 128.37, down from 6189.89 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 6189.89 in Q1 2026, with the low at 0.98 in Q3 2023.
- The 5-year median for Interest Coverage Ratio is 7.33 (2022), against an average of 593.6.
- The sharpest annual moves came in 2023 and 2026: Interest Coverage Ratio tumbled 126.49% in 2023, then soared 326071.19% in 2026.
- Exelixis' Interest Coverage Ratio stood at 0.62 in 2022, then soared by 258.29% to 0.99 in 2023, then soared by 11918.4% to 118.43 in 2024, then soared by 2493.91% to 3071.95 in 2025, then slumped by 95.82% to 128.37 in 2026.
- Business Quant data shows EXEL's Interest Coverage Ratio at 128.37 in Q2 2026, 6189.89 in Q1 2026, and 3071.95 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 28, 2018 | -111,602.00 |
| Sep 28, 2018 | 125,176.00 |
| Jun 30, 2017 | 6.37 |
| Mar 31, 2017 | 4.57 |
| Dec 30, 2016 | 8.67 |
| Sep 30, 2016 | 0.93 |
| Jun 30, 2016 | -2.41 |
| Mar 31, 2016 | -4.78 |
| Sep 30, 2015 | -3.56 |
| Jun 30, 2015 | -2.62 |
| Mar 31, 2015 | -1.84 |
| Dec 31, 2014 | -8.82 |
| Sep 30, 2014 | -4.20 |
| Jun 30, 2014 | -5.11 |
| Mar 31, 2014 | -5.53 |
| Dec 31, 2013 | -11.78 |
| Sep 30, 2013 | -4.89 |
| Jun 30, 2013 | -4.56 |
| Mar 31, 2013 | -3.08 |
| Dec 31, 2012 | -4.66 |